Archives
-
CasKAS Maps CRISPR Specificity Through ssDNA
2026-09-11
CasKAS uses chemical labeling of the single-stranded DNA exposed during Cas9 or dCas9 binding to profile CRISPR specificity across the genome. The study presents a comparatively rapid and accessible strategy that can detect both catalytically active and inactive CRISPR enzymes in vitro and in cells, complementing cleavage- and occupancy-based assays.
-
TPCA-1 in Septic AKI: From NF-κB to Assay Design
2026-09-11
Explore how TPCA-1, a selective IKK-2 inhibitor, can help researchers test the NF-κB/Apaf1/caspase-9/autophagy axis in septic acute kidney injury. This article translates a 2026 mechanistic study into a causal, time-resolved assay strategy rather than repeating standard inhibitor guidance.
-
From Tagged Proteins to Translational Mechanism
2026-09-10
A thought-leadership guide connecting X-press Tag Peptide-enabled purification with mechanistic studies of RHEB neddylation, mTORC1 signaling, liver disease, and translational assay design.
-
Canagliflozin Hemihydrate: Beyond SGLT2
2026-09-10
Canagliflozin hemihydrate is more than a reagent for glucose transport studies. By pairing its SGLT2-centered mechanism with orthogonal mTOR counterscreens, translational researchers can separate renal glucose reabsorption biology from broader nutrient-signaling hypotheses and build more defensible diabetes research programs.
-
EGCG Workflows for Apoptosis and IVDD Research
2026-09-09
Build reproducible EGCG experiments spanning apoptosis assays, antiviral research, antiangiogenic screening, and inflammation-focused biomaterials. This guide pairs practical dosing and handling advice with the reference study’s stimulus-responsive hydrogel strategy.
-
CMA Decline Drives Age-Related Skeletal Muscle Myopathy
2026-09-09
This study identifies chaperone-mediated autophagy (CMA) as an active regulator of skeletal muscle maintenance rather than a passive response to aging. Using muscle-specific LAMP2A loss, proteomic analysis, and rescue experiments, the authors connect impaired CMA to SERCA turnover, calcium dysregulation, mitochondrial proteome changes, and progressive myopathy.
-
Ciprofloxacin Beyond Antibiotics: A Translational Playbook
2026-09-08
Ciprofloxacin is more than a conventional fluoroquinolone antibiotic. Its established DNA-targeting biology now supports research spanning antimicrobial resistance, bacterial infection models, and emerging nanotheranostic platforms. This thought-leadership guide connects mechanism, assay design, formulation discipline, and translational strategy while examining evidence from a 2026 ultrasound-guided ZIF8 cancer study.
-
GCLC Truncation and Delayed Age-Related Cataract
2026-09-08
Wei et al. identify age-associated truncation of the GCLC catalytic subunit as a mechanistic driver of declining lenticular glutathione and demonstrate that preventing this processing event delays cataract formation in mice. The D499E knock-in model provides a causal framework for studying redox maintenance in the aging lens and for separating cataract prevention from treatment of established opacity.
-
Rottlerin PKC Inhibition: Cell Entry Workflows
2026-09-07
Rottlerin provides a practical way to probe PKCδ-linked signaling across cell proliferation, apoptosis, endothelial barrier function, and pathogen entry. This workflow-focused guide connects concentration control, uptake assays, and orthogonal viability readouts to the endocytic findings reported in Drosophila S2 cells.
-
Imidazoline Antagonists and β-Cell K+ Channels
2026-09-07
The 1992 study showed that several imidazoline α2-adrenoceptor antagonists stimulate insulin release primarily by inhibiting ATP-sensitive K+ channels in pancreatic β-cells, rather than through adrenergic antagonism alone. Its combination of 86Rb efflux, insulin-secretion experiments, and patch-clamp electrophysiology provides a useful framework for separating receptor-mediated effects from direct ion-channel actions.
-
Ciprofloxacin Workflows for AMR and Nanotheranostics
2026-09-05
Ciprofloxacin supports two complementary research paths: quantitative antibacterial assays and ultrasound-responsive nanotheranostic development. This guide connects its fluoroquinolone mechanism of action with practical formulation, resistance-modeling, release-testing, and troubleshooting workflows.
-
RESTRICT-seq Maps KAT6A-Linked SCC Resistance
2026-09-04
The RESTRICT-seq preprint introduces a time-gated CRISPR screening strategy for separating epigenetic dependencies associated with the establishment and maintenance of squamous cell carcinoma resistance. Its identification of KAT6A as a resistance-linked vulnerability connects temporal functional genomics with oncogene-induced senescence and provides a rationale for pharmacological validation in cancer biology research.
-
Pemetrexed as a Mechanistic Assay Probe
2026-09-04
Pemetrexed is more than a cytotoxic readout: it is a mechanistic probe for folate-dependent nucleotide stress in tumor models. This article shows how to pair pemetrexed response profiling with DNA-repair phenotyping, using malignant mesothelioma research as a practical example.
-
Ciprofloxacin Workflows for Resistance Research
2026-09-03
Ciprofloxacin is more than a routine susceptibility control: it is a mechanistic probe for DNA replication inhibition and a practical comparator in plasmid-mediated resistance studies. This guide translates recent CREC transmission findings into solvent-aware assay workflows, controls, and troubleshooting decisions for antimicrobial resistance research.
-
NF449 Reveals a Platelet P2X1 Antithrombotic Axis
2026-09-03
The reference study established NF449 as a pharmacological tool for separating platelet P2X1 signaling from P2Y1- and P2Y12-mediated responses. Its dose-dependent inhibition of platelet activation and experimental thrombosis, with no significant bleeding-time prolongation at a selective dose, provides a mechanistic framework for platelet aggregation inhibition research while highlighting important selectivity limits.